- Home
- GH vs EXG Comparison
GH vs EXG Comparison
Compare GH & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- EXG
- Stock Information
- Founded
- GH 2011
- EXG 2007
- Country
- GH United States
- EXG United States
- Employees
- GH N/A
- EXG N/A
- Industry
- GH Medical Specialities
- EXG Finance Companies
- Sector
- GH Health Care
- EXG Finance
- Exchange
- GH Nasdaq
- EXG Nasdaq
- Market Cap
- GH 2.7B
- EXG 2.5B
- IPO Year
- GH 2018
- EXG N/A
- Fundamental
- Price
- GH $30.98
- EXG $8.38
- Analyst Decision
- GH Strong Buy
- EXG
- Analyst Count
- GH 15
- EXG 0
- Target Price
- GH $39.93
- EXG N/A
- AVG Volume (30 Days)
- GH 2.2M
- EXG 533.2K
- Earning Date
- GH 11-06-2024
- EXG 01-01-0001
- Dividend Yield
- GH N/A
- EXG 8.27%
- EPS Growth
- GH N/A
- EXG N/A
- EPS
- GH N/A
- EXG N/A
- Revenue
- GH $692,256,000.00
- EXG N/A
- Revenue This Year
- GH $31.00
- EXG N/A
- Revenue Next Year
- GH $17.55
- EXG N/A
- P/E Ratio
- GH N/A
- EXG N/A
- Revenue Growth
- GH 29.20
- EXG N/A
- 52 Week Low
- GH $15.81
- EXG $6.78
- 52 Week High
- GH $37.04
- EXG $8.15
- Technical
- Relative Strength Index (RSI)
- GH 70.13
- EXG 43.69
- Support Level
- GH $28.45
- EXG $8.31
- Resistance Level
- GH $32.26
- EXG $8.51
- Average True Range (ATR)
- GH 1.70
- EXG 0.12
- MACD
- GH 0.39
- EXG -0.01
- Stochastic Oscillator
- GH 75.19
- EXG 18.06
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks with an emphasis on dividend-paying stocks and writes call options on one or more U.S. and foreign indices with respect to a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.